Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-04
2005-10-04
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S324000, C514S372000, C514S373000, C514S374000, C514S375000, C514S376000, C514S377000
Reexamination Certificate
active
06951873
ABSTRACT:
Methods for the treatment of age-related behavioral disorders in companion animals are disclosed. These comprise administering to a companion animal in need of such treatment a therapeutically effective amount of an acetylcholinesterase inhibitor. A preferred acetylcholinesterase inhibitor is a compound of Formula 1:Pharmaceutical compositions and dosage forms comprising a compound of Formula 1 are also disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3847770 (1974-11-01), Radlowe et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4687610 (1987-08-01), Vassilatos
patent: 4769027 (1988-09-01), Baker et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354566 (1994-10-01), Addesso et al.
patent: 5494908 (1996-02-01), O'Malley et al.
patent: 5538984 (1996-07-01), Villalobos et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5750542 (1998-05-01), Villalobos et al.
patent: 9217475 (1992-10-01), None
Giovannini et al., “Effect of subchronic treatment with metrifonate and tacrine on brain cholinergic function in aged F344 rats”, abstract to Eur. J. Pharmacol. 354(1), pp. 17-24, 1998.
Bryson, et al., “Donepezil”, Abstract from Drugs Aging 10(3), pp. 234-239, 1997.
Cheng, et al., “Huperzine a, a novel promising acetylcholinesterase inhibitor”, abstract to NeuroReport, 8(1), pp. 97-101, 1996.
Leonard, et al., “Pontine nitric oxide modulates acetylcholine release, rapid eye movement sleep generation, and respiratroy rate”, Journal of Neuroscience, vol. 17, No. 2, pp. 774-785, 1997.
Cummings, et al.; β-Amyloid Accumulation Correlates with Cognitive Dysfunction in the Aged Canine; Neurobiology of learning and Memory; vol. 66, pp 11-23, (1996).
Ruehl, et al.; Canine Cognitive Dysfunction; Psychopharmacology of Animal Behavior Disorders; pp 283-304, (1998).
Corey-Bloom, et al.; Monoamine Oxidase Inhibitors in Alzheimer's Disease; Monoamine Oxidase Inhibitors in Neurological Diseases; pp. 279-294 (1994).
Finnegan; Inhibition of Monoamine Oxidase B and the Neuroprotective Effects of Selegiline; Monamine Oxidase Inhibitors in Neurological Diseases; pp. 210-216 (1994).
Hart, et al.; Selecting, Raising, and Caring for Dogs to avoid Problem Aggression; JAVMA, vol. 210, No. 8; pp 1129-1134 (1997).
Ruehl, et al.; Canine Cognitive Dysfunction as a Model for Human age-related Cognitive Decline, Dementia and Alzheimer's Disease; Progress in Brain Research; vol. 106: 217-225, (1995).
Ruehl, et al.; Therapeutic Actions of L-Deprenyl in Dogs: A Model of Human Brain Aging; Advances in Pharmacology; vol. 42: pp 316-319, (1998).
E. Head, et al.; Spatial Learning and Memory as a Function of Age in the Dog; Behavioral Neuroscience; vol. 109, pp 851-858 (1995).
E. Head, et al.; The Effects of L-Deprenyl on Spatial Short Term Memory in Young and aged Dogs; Prog. Neuro-Psychopharmacol. & Biol. Psychiatry; vol. 20, pp 515-530, (1996).
Mimori, et al.; Abnormalities of Acetylcholinesterase in Alzheimer's Disease with Special Reference to effect of Acetylcholinesterase Inhibitor; Behav. Brain Res. vol., 83, pp. 25-30, (1997).
Ellman, et al.; A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity; Biochemical Pharmacology; vol. 7, pp 88-95 (1960).
Jones Dwayne
Ling Lorraine B.
Myers Jeffrey N.
Pfizer Inc.
Richardson Peter C.
LandOfFree
Methods for treating age-related behavioral disorders in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating age-related behavioral disorders in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating age-related behavioral disorders in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446167